Flibanserin hydrochloride  (Synonyms: BIMT-17 hydrochloride; BIMT-17BS hydrochloride)

Flibanserin hydrochloride (BIMT-17 hydrochloride) is an orally active 5-HT_1A receptor agonist and 5-HT_2A receptor antagonist with binding affinities K_i of 1 nM and 49 nM, respectively. Flibanserin hydrochloride also binds to dopamine D4 receptors with a K_i of 4-24 nM. Flibanserin hydrochloride has antidepressant and anxiolytic effects and can be used in the study of hypoactive sexual desire disorder (HSDD)^[1].

426.86

C₂₀H₂₂ClF₃N₄O

147359-76-0

O=C1NC2=C(N1CCN3CCN(CC3)C4=CC=CC(C(F)(F)F)=C4)C=CC=C2.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. El-Behairy, et al. "Insights into flibanserin oxidative stress degradation pathway: in silico–in vitro toxicity assessment of its degradates." New Journal of Chemistry 45.5 (2021): 2620-2630.

  [2]. Invernizzi, Roberto William, et al. "Flibanserin, a potential antidepressant drug, lowers 5‐HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5‐HT1A receptors." British journal of pharmacology 139.7 (2003): 1281-1288.  [Content Brief]

  [3]. Gelez, et al. "Brain neuronal activation induced by flibanserin treatment in female rats." Psychopharmacology 230 (2013): 639-652.  [Content Brief]

  [4]. Podhorna, et al. "Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety." British journal of pharmacology 130.4 (2000): 739-746.  [Content Brief]

  [5]. Gelman, et al. "Flibanserin for hypoactive sexual desire disorder: place in therapy." Therapeutic Advances in Chronic Disease 8.1 (2017): 16-25.  [Content Brief]